Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28548119 | 1.00 | MAPT (0.67) | MAPTKDM4EMEN1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL27358254 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL29151371 | 0.88 | MAPT (0.61) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL23723484 | 0.88 | MAPT (0.76) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL29472033 | 0.88 | MAPT (0.76) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL289044 | 0.86 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL475351 | 0.86 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL27495642 | 0.86 | KDM4E (0.66) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL626831 | 0.85 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL28780405 | 0.85 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834265-A | Polypeptide with complement inhibition activity, fusion protein and medical application thereof | 北京拓界生物医药科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240218018-A1 | Compstatin Analogs with Increased Solubility and Improved Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-07-04 | — | — | US | disclosed |
| US-11884747-B2 | Compstatin analogs with increased solubility and improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-01-30 | — | — | US | disclosed |
| CN-110229216-B | Compstatin peptides with improved pharmacokinetic properties | 宾夕法尼亚州大学理事会 | 2023-06-16 | — | — | CN | disclosed |
| EP-4011905-A2 | COMPSTATIN ANALOGS WITH INCREASED SOLUBILITY AND IMPROVED PHARMACOKINETIC PROPERTIES | The Trustees Of The University Of Pennsylvania (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3645550-B1 | COMPSTATIN ANALOGS WITH INCREASED SOLUBILITY AND IMPROVED PHARMACOKINETIC PROPERTIES | UNIV PENNSYLVANIA (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-112334477-A | Compstatin analogs with increased solubility and improved pharmacokinetic properties | 宾夕法尼亚大学理事会 | 2021-02-05 | — | — | CN | disclosed |
| US-20210032291-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-02-04 | — | — | US | disclosed |
| CN-112041330-A | Compstatin analogs and medical uses thereof | 西兰制药第三特殊目的公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10800812-B2 | Compstatin analogs with increased solubility and improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-10-13 | — | — | US | disclosed |
| EP-0405537-A1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER-LAMBERT COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0403600-A1 | DEPROTECTION OF PROTECTED PEPTIDES | THE ROCKEFELLER UNIVERSITY (US) | 1990-12-27 | — | — | EP | disclosed |
| WO-1990013563-A1 | SYNTHETIC PSEUDOMONAS AERUGINOSA PILIN PEPTIDE AND RELATED VACCINES AND DIAGNOSTICS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1990-11-15 | — | — | WO | disclosed |
| WO-1990002138-A1 | DEPROTECTION OF PROTECTED PEPTIDES | THE ROCKEFELLER UNIVERSITY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0349354-A1 | Peptides PF10 to PF19 from a retro virus HIV, method for the synthesis of these peptides and their use, particularly in diagnostics | INSTITUT PASTEUR (FR) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989009227-A2 | PF10 TO PF19 PEPTIDES OF AN HIV RETROVIRUS, PROCESS FOR SYNTHETIZING SAID PEPTIDES AND THEIR USE, IN PARTICULAR FOR DIAGNOSIS | INSTITUT PASTEUR (FR) | 1989-10-05 | — | — | WO | disclosed |
| EP-0284383-A1 | Synthetic antigens for the detection of aids-related disease caused by LAV-2 | GENETIC SYSTEMS CORPORATION (US) | 1988-09-28 | — | — | EP | disclosed |
| WO-1988005051-A1 | SYNTHETIC PEPTIDES WHICH INDUCE CELLULAR IMMUNITY OF THE AIDS VIRUS AND AIDS VIRAL PROTEINS | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0273716-A2 | Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4507230-A | DETACHING RESINS FROM PEPTIDES | RESEARCH CORPORATION (US) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032291-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | VIP, C1QBP, C9 | MAPT 3025/4885KDM4E 4593/4885MEN1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.